Placental Site Trophoblastic Tumor: Diagnostic and Therapeutic Advancement and A Case Report

XIAO Ping,YIN Ru-tie,TONG Long-xia,WANG Dan-qing,LI Qing-li
2012-01-01
Abstract:Objective To introduce the clinicopathological characteristics,treatments and prognosis of placental site trophoblastic tumor(PSTT) by reviewing a PSTT case and its related literatures.Methods We retrospectively studied a rare case of PSTT primarily locating in the uterine cervix in our hospital,and reviewed the related literatures in PubMed and CNKI(China National Knowledge Infrastructure) databases using placental site trophoblastic tumor as the subject word.Results The patient had a good condition after receiving operation and chemotherapy without any evidence of recurrence of metastasis during the 3-year follow-up.Before September 1st,2011,there were more than 160 cases reported in PubMed database including 2 cases of PSTT occurring in uterine cervix,and more than 300 cases in CNKI database.PSTT occurring in uterine cervix was rare and easy to be misdiagnosed,and histopathological diagnosis was necessary for the diagnosis.Conclusions Whether there are differences in the prognosis between PSTT occurring in cervix and uterine remains to be verified by more samples.The incidence of PSTT is rare,and there are no specific clinical features,so it is often diagnosed by curettage,biopsy or even postoperative pathologic results.PSTT is insensitive to chemotherapeutic drugs,and the preferred therapy is operation.Most patients can get complete remission after foci eradication.To improve the prognosis of patients with high risks of recurrence and metastasis,EMA-CO(etoposide,methotrexate,actinomycinD,alternating with cyclophosphamide and vincristine) or EMA-EP(etoposide,methotrexate,actinomycinD,alternating with etoposide and cisplatin) chemotherapy is needed after operation.
What problem does this paper attempt to address?